Compare Neurocrine Biosciences Inc (NBIX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prologis Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while Prologis Inc trades at $151.05 (market cap $137.50B). The key difference: Prologis Inc is far larger — about 7.9× Neurocrine Biosciences Inc's market cap, and Prologis Inc pays a 2.9% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | PLD | |
|---|---|---|
Market Cap | $17.40B | $137.50B |
Sector | Health | Real Estate |
52-Week High | $180.55 | $149.96 |
52-Week Low | $123.10 | $104.08 |
Enterprise Value | $16.49B | $172.18B |
Dividend Yield | — | 2.9% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
